Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

NCT04285671 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Refractory Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL: Necitumumab
DRUG: Osimertinib
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
BIOLOGICAL: Trastuzumab

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]